RATIONALE: In the myocardium, redox/cysteine modification of proteins regulating Ca(2+) cycling can affect contraction and may have therapeutic value. Nitroxyl (HNO), the one-electron-reduced form of nitric oxide, enhances cardiac function in a manner that suggests reversible cysteine modifications of the contractile machinery. OBJECTIVE: To determine the effects of HNO modification in cardiac myofilament proteins. METHODS AND RESULTS: The HNO-donor, 1-nitrosocyclohexyl acetate, was found to act directly on the myofilament proteins, increasing maximum force (F(max)) and reducing the concentration of Ca(2+) for 50% activation (Ca(50)) in intact and skinned cardiac muscles. The effects of 1-nitrosocyclohexyl acetate are reversible by reducing agents and distinct from those of another HNO donor, Angeli salt, which was previously reported to increase F(max) without affecting Ca50. Using a new mass spectrometry capture technique based on the biotin switch assay, we identified and characterized the formation by HNO of a disulfide-linked actin-tropomyosin and myosin heavy chain-myosin light chain 1. Comparison of the 1-nitrosocyclohexyl acetate and Angeli salt effects with the modifications induced by each donor indicated the actin-tropomyosin and myosin heavy chain-myosin light chain 1 interactions independently correlated with increased Ca(2+) sensitivity and force generation, respectively. CONCLUSIONS: HNO exerts a direct effect on cardiac myofilament proteins increasing myofilament Ca(2+) responsiveness by promoting disulfide bond formation between critical cysteine residues. These findings indicate a novel, redox-based modulation of the contractile apparatus, which positively impacts myocardial function, providing further mechanistic insight for HNO as a therapeutic agent.
RATIONALE: In the myocardium, redox/cysteine modification of proteins regulating Ca(2+) cycling can affect contraction and may have therapeutic value. Nitroxyl (HNO), the one-electron-reduced form of nitric oxide, enhances cardiac function in a manner that suggests reversible cysteine modifications of the contractile machinery. OBJECTIVE: To determine the effects of HNO modification in cardiac myofilament proteins. METHODS AND RESULTS: The HNO-donor, 1-nitrosocyclohexyl acetate, was found to act directly on the myofilament proteins, increasing maximum force (F(max)) and reducing the concentration of Ca(2+) for 50% activation (Ca(50)) in intact and skinned cardiac muscles. The effects of 1-nitrosocyclohexyl acetate are reversible by reducing agents and distinct from those of another HNOdonor, Angeli salt, which was previously reported to increase F(max) without affecting Ca50. Using a new mass spectrometry capture technique based on the biotin switch assay, we identified and characterized the formation by HNO of a disulfide-linked actin-tropomyosin and myosin heavy chain-myosin light chain 1. Comparison of the 1-nitrosocyclohexyl acetate and Angeli salt effects with the modifications induced by each donor indicated the actin-tropomyosin and myosin heavy chain-myosin light chain 1 interactions independently correlated with increased Ca(2+) sensitivity and force generation, respectively. CONCLUSIONS:HNO exerts a direct effect on cardiac myofilament proteins increasing myofilament Ca(2+) responsiveness by promoting disulfide bond formation between critical cysteine residues. These findings indicate a novel, redox-based modulation of the contractile apparatus, which positively impacts myocardial function, providing further mechanistic insight for HNOas a therapeutic agent.
Authors: Nazareno Paolocci; Tatsuo Katori; Hunter C Champion; Marcus E St John; Katrina M Miranda; Jon M Fukuto; David A Wink; David A Kass Journal: Proc Natl Acad Sci U S A Date: 2003-04-18 Impact factor: 11.205
Authors: N Paolocci; W F Saavedra; K M Miranda; C Martignani; T Isoda; J M Hare; M G Espey; J M Fukuto; M Feelisch; D A Wink; D A Kass Journal: Proc Natl Acad Sci U S A Date: 2001-08-21 Impact factor: 11.205
Authors: Katrina M Miranda; Nazareno Paolocci; Tatsuo Katori; Douglas D Thomas; Eleonora Ford; Michael D Bartberger; Michael G Espey; David A Kass; Martin Feelisch; Jon M Fukuto; David A Wink Journal: Proc Natl Acad Sci U S A Date: 2003-07-15 Impact factor: 11.205
Authors: Junhui Sun; Angel M Aponte; Sara Menazza; Marjan Gucek; Charles Steenbergen; Elizabeth Murphy Journal: Cardiovasc Res Date: 2016-02-17 Impact factor: 10.787
Authors: Fouad A Zouein; Lisandra E de Castro Brás; Danielle V da Costa; Merry L Lindsey; Mazen Kurdi; George W Booz Journal: J Cardiovasc Pharmacol Date: 2013-07 Impact factor: 3.105